Satio and Nanowear have entered a strategic partnership to revolutionize remote healthcare by integrating their advanced technologies. This collaboration combines Nanowear’s AI-powered, at-home nanotechnology diagnostic platform with Satio’s innovative blood draw and drug delivery patches. Together, they aim to offer a unified, time-synchronous solution that merges in vivo and in vitro diagnostics for truly personalized and precise therapeutic care.
Addressing the Gaps in Home-Based Healthcare
Although home-based digital healthcare has gained momentum since 2019, its widespread adoption remains limited due to persistent issues such as cost, accuracy, workflow inefficiencies, and a lack of actionable, interoperable data. These limitations have led to underutilization and frustration among stakeholders, highlighting a pressing need for integrated, reliable remote healthcare solutions.
Nanowear’s SimpleSense™: A Comprehensive At-Home Diagnostic Platform
Nanowear leads the way in transforming cardiometabolic care at home through its FDA-approved cloth-based nanotechnology and AI diagnostic solution, SimpleSense™. This platform collects over 85 clinically validated cardiopulmonary and hemodynamic biomarkers simultaneously, delivering a complete picture of a patient’s health in real time. SimpleSense™ replaces traditional diagnostic tools such as multi-channel ECGs, digital stethoscopes, blood pressure monitors, and even incorporates continuous glucose monitoring through a recent data partnership.
Satio’s Innovation in Decentralized Diagnostics and Drug Delivery
Satio has been redefining decentralized healthcare by enabling blood-based diagnostics and drug delivery outside clinical settings. With adhesive patch-based technologies like SatioDot for dry blood spot collection and SatioDraw for whole blood draws, Satio empowers patients to receive care at home. The company was recently recognized for completing the first ARPA-H Challenge program. This recognition further validates its technological edge and commitment to remote care innovation.
Integration for a Unified, Data-Rich Digital Health Platform
By combining their platforms, Satio and Nanowear aim to deliver an unprecedented level of data accuracy and integration. One key initiative involves merging Satio’s blood collection technologies with Nanowear’s SimpleSense app. This integration will enable the collection of both blood/genetic biomarkers and physiological data in one interface. It marks a first-of-its-kind development in biopharma, medtech, and clinical research.
In another use case, Nanowear’s biomarkers will enhance SatioRx’s telehealth-based drug delivery system. This dynamic platform will support real-time diagnostics, monitoring, and care—targeting a global home-based care market valued at approximately $200 billion.
Accelerating Innovation Through Strategic Collaboration
As reported by advamed.org, the two companies plan to jointly promote their combined technologies. They aim to target stakeholders across healthcare, clinical research, and pharma industries. Their goal is to accelerate the shift from centralized, clinic-based care to decentralized, patient-friendly models without compromising data quality or care precision.
Leaders Speak: The Future of Digital Health
“We’re thrilled to unite in vitro and in vivo diagnostics to improve chronic disease, cardiometabolic, and cancer care,” said Namal Nawana, Chairman and Founder of Satio. “For real decentralization, we need to not just reimagine workflow but also enhance information flow—ensuring clinicians receive reliable data and patients experience peace of mind.”
Venk Varadan, CEO and Co-founder of Nanowear, added, “Each person’s health systems communicate in unique ways. By combining these determinants—genes, blood, cardiopulmonary and metabolic markers—our partnership unlocks a first-of-its-kind diagnostic platform that empowers early diagnosis and personalized treatment.”
He continued, “Precision medicine, early diagnosis, and individualized risk assessment have been buzzwords in digital health since the pandemic. What’s held us back is the inability to capture all relevant biomarkers in sync. With this collaboration, we finally have a real-time data pipeline to drive meaningful AI-powered precision care.”
Currently, Satio products are not yet approved for use in the United States or other markets.